Imagine your body's chemistry as a giant map of interconnected roads. In some rare diseases, a few roads are blocked, but it's hard to find exactly where the jam is. This project builds a digital twin of a patient's metabolism to pinpoint the exact blockage and suggest a personalized treatment plan.
Diagnosing rare inherited metabolic diseases is often slow and imprecise, leading to delayed treatment. There is a lack of standardized, regulatory-compliant software that can personalize treatment based on a patient's unique genetic and metabolic profile.
A regulatory-compliant software medical device that generates personalized computational models of human metabolism. It includes the PROTRIDER algorithm for proteomic analysis and a clinical data platform called IMD-Hub.
If you are a diagnostic lab dealing with long delays in identifying rare metabolic disorders — this project developed regulatory-compliant software that uses genomic and proteomic data to accelerate diagnosis. It leverages models trained on 1,945 patients to find answers faster.
If you are a biotech company dealing with unpredictable patient responses to metabolic drugs — this project developed personalized computational models that identify compensatory mechanisms. This allows for better patient stratification using data from 1,945 diagnosed cases.
If you are a software vendor dealing with a lack of specialized tools for rare disease management — this project developed a software medical device designed for clinician access. It integrates deep learning-based protein structure prediction into a usable interface.
Based on available project data, no specific pricing or cost details are provided.
The project aims for broad applicability across various inherited metabolic diseases and is designing the software to be accessible to clinicians and regulatory-compliant, suggesting a path toward scale.
Based on available project data, specific licensing terms are not mentioned, though the project is developing a roadmap for a European foundation to ensure long-term impact.
Yes, the project explicitly states that the software is being implemented to be admissible to regulatory authorities as a software medical device.
The project runs from 2023-06-01 to 2027-05-31, with the software development occurring within this window.
The consortium is heavily academic, consisting of 19 universities and 9 research organizations across 13 countries. With 0% industry participation and 0 SMEs, the project is currently a research-driven initiative. This indicates a high level of scientific rigor but a potential gap in immediate commercialization expertise, which may be addressed by the proposed European foundation.
Contact the University of Galway regarding the software medical device implementation.
Contact us to find a commercial partner to bridge the gap between this academic research and market entry.
